Trump Order Eases FDA Restrictions on Psychedelics

President Donald Trump signed an executive order aimed at accelerating research into psychedelic treatments for post-traumatic stress disorder (PTSD), according to Bloomberg News.

Ibogaine isa psychoactive compound derived from an African plant that has been studied for its potential to treat addiction, depression, and PTSD. (Photo: NZ Drug Foundation)

The order directs the U.S. Food and Drug Administration (FDA) to issue guidance on ibogaine, a psychoactive compound derived from an African plant that has been studied for its potential to treat addiction, depression, and PTSD.

Although ibogaine remains a Schedule I controlled substance in the United States, Trump urged health officials to consider reclassification.

The order also allocates $50 million for research and expands access for terminally ill patients under the Right to Try law.

While early studies suggest ibogaine may reduce opioid withdrawal symptoms, experts caution that evidence remains limited and the compound carries serious risks, including cardiac complications.